Chronic Lymphocytic Leukemia

>

Latest News

Antitumor Activity and BTK Degradation Is Observed With NX-2127 in R/R CLL
Antitumor Activity and BTK Degradation Is Observed With NX-2127 in R/R CLL

March 7th 2023

Acquired resistance to BTK inhibitors is a new and growing challenge in the treatment of CLL and dual resistance to BTK and BCL2 is occurring in more patients, according to Lindsey Roeker, MD.

AVO Triplet Regimen Continues to Show Durable Responses in High-Risk CLL
AVO Triplet Regimen Continues to Show Durable Responses in High-Risk CLL

March 6th 2023

Comparison of BTK Inhibitors Shows Promising Results for Zanubrutinib Over Ibrutinib in CLL/SLL
Comparison of BTK Inhibitors Shows Promising Results for Zanubrutinib Over Ibrutinib in CLL/SLL

February 14th 2023

Allan Explores Data on Frontline BTK Inhibition for CLL Treatment
Allan Explores Data on Frontline BTK Inhibition for CLL Treatment

February 9th 2023

More News